Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

ANIP Insider Trading

Ani Pharmaceuticals Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Ani Pharmaceuticals Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2019-05-29 23:00 2019-05-24 NASH DAVID Director BUY $68.76 1,445 $99,358 5,236 +38.1%
2019-05-20 23:32 2019-05-17 Marken James G. Officer - SVP Ops & Prod Dev SELL $70.67 8,907 $629,458 61,230 -12.7%
2019-05-16 00:16 2019-05-13 PRZYBYL ARTHUR Director, Officer - President and CEO SELL $70.07 30,000 $2,102,178 202,589 -12.9%
2019-05-15 23:32 2019-05-15 HAUGHEY THOMAS Director BUY $69.30 2,500 $173,240 6,291 +65.9%
2019-05-15 23:32 2019-05-14 Marken James G. Officer - SVP Ops & Prod Dev SELL $70.31 4,917 $345,714 70,137 -6.6%
2019-05-13 23:01 2019-05-13 Schrepfer Robert W Officer - SVP - New Bus Dev & Spec Sales SELL $71.13 2,409 $171,352 55,927 -4.1%
2019-03-20 23:07 2019-03-18 PRZYBYL ARTHUR Director, Officer - President and CEO OPT+S $63.53 27,625 $1,754,961 205,076 0.0%
2019-03-14 13:02 2019-03-12 Schrepfer Robert W Officer - SVP - New Bus Dev & Spec Sales OPT+S $64.44 11,796 $760,167 47,842 0.0%
2018-05-16 23:22 2018-05-14 MARSHBANKS TRACY Director SELL $62.33 38,236 $2,383,193 349,934 -9.9%
2018-05-12 01:30 2018-05-09 MARSHBANKS TRACY Director SELL $62.07 62,431 $3,874,949 388,170 -13.9%
2018-04-20 01:33 2018-04-18 MARSHBANKS TRACY Director SELL $62.09 33,200 $2,061,388 450,601 -6.9%
2018-03-19 23:54 2018-03-15 RAYNOR DANIEL Director SELL $60.85 7,215 $439,047 289,003 -2.4%
2018-03-17 00:54 2018-03-14 MARSHBANKS TRACY Director SELL $63.10 1,912 $120,647 483,801 -0.4%
2018-03-15 02:02 2018-03-13 PRZYBYL ARTHUR Director, Officer - President and CEO OPT+S $61.83 40,000 $2,473,144 185,706 0.0%
2018-03-15 00:33 2018-03-12 RAYNOR DANIEL Director SELL $62.24 27,964 $1,740,552 296,218 -8.6%
2018-03-13 02:26 2018-03-08 MARSHBANKS TRACY Director SELL $63.03 64,221 $4,047,888 485,713 -11.7%
2018-03-08 01:00 2018-03-05 Marken James G. Officer - SVP Ops & Prod Dev OPT+S $61.92 4,177 $258,640 65,470 0.0%
2018-03-06 01:01 2018-03-01 Schrepfer Robert W Officer - SVP - New Bus Dev & Spec Sales OPT+S $61.66 28,652 $1,766,771 12,938 0.0%
2018-03-06 01:00 2018-03-01 PRZYBYL ARTHUR Director, Officer - President and CEO OPT+S $61.23 23,986 $1,468,694 209,983 0.0%
2016-08-23 23:14 2016-08-22 PRZYBYL ARTHUR Director, Officer - President and CEO OPT+S $66.97 37,455 $2,508,361 191,806 0.0%
2016-08-09 23:30 2016-08-08 Schrepfer Robert W Officer - VP Bus Dev & Con Mfg SELL $67.06 12,500 $838,209 17,362 -41.9%
2015-12-23 00:23 2015-12-18 Marken James G. Officer - Vice President, Operations SELL $43.26 3,500 $151,410 45,983 -7.1%
2015-11-13 00:44 2015-11-12 PRZYBYL ARTHUR Director, Officer - President and CEO BUY $40.95 2,500 $102,375 145,195 +1.8%
2015-03-19 23:55 2015-03-19 Marken James G. Officer - Vice President, Operations SELL $66.50 15,000 $997,500 31,568 -32.2%
2015-03-17 04:30 2015-03-12 MARSHBANKS TRACY Director SELL $63.00 210,000 $13,230,000 5,870 -97.3%
2015-03-17 00:45 2015-03-12 Arnold Charlotte C. Officer - Vice President and CFO SELL $63.00 45,000 $2,835,000 21,385 -67.8%
2015-03-17 00:43 2015-03-12 PRZYBYL ARTHUR Director, Officer - President and CEO SELL $63.00 75,000 $4,725,000 114,164 -39.6%
2015-03-17 00:36 2015-03-12 MERIDIAN VENTURE PARTNERS II LP 10% owner SELL $63.00 300,000 $18,900,000 2,350,559 -11.3%
2015-03-17 00:32 2015-03-12 RAYNOR DANIEL Director SELL $63.00 200,000 $12,600,000 324,182 -38.2%
2014-09-16 23:40 2014-09-15 MANGANO ROSS J Director BUY $27.49 3,000 $82,477 26,914 +12.5%
2014-09-10 00:56 2014-09-09 PRZYBYL ARTHUR Director, Officer - President and CEO BUY $26.50 1,000 $26,500 189,162 +0.5%
2014-03-21 21:43 2014-03-20 MARSHBANKS TRACY Director SELL $31.42 21,767 $683,852 8,111 -72.9%
2014-03-21 03:44 2014-03-19 MERIDIAN VENTURE PARTNERS II LP 10% owner SELL $32.12 20,922 $671,990 2,650,559 -0.8%
2014-03-20 00:13 2014-03-18 MARSHBANKS TRACY Director SELL $33.68 25,358 $854,169 8,350 -75.2%
2014-03-19 03:49 2014-03-14 MERIDIAN VENTURE PARTNERS II LP 10% owner SELL $34.07 60,540 $2,062,307 2,671,481 -2.2%
2014-03-19 03:46 2014-03-14 RAYNOR DANIEL Director SELL $33.85 12,347 $417,946 524,182 -2.3%
2014-03-19 03:51 2014-03-12 MERIDIAN VENTURE PARTNERS II LP 10% owner SELL $32.48 87,723 $2,849,252 2,732,021 -3.1%
2014-03-19 03:44 2014-03-12 RAYNOR DANIEL Director SELL $33.90 21,111 $715,557 536,529 -3.8%
2014-03-15 02:23 2014-03-12 RAYNOR DANIEL Director SELL $33.89 21,111 $715,452 3,324,738 -0.6%
2014-03-15 02:20 2014-03-12 MERIDIAN VENTURE PARTNERS II LP 10% owner SELL $32.48 87,723 $2,849,524 16,830,746 -0.5%
2013-11-12 22:29 2013-11-07 MANGANO ROSS J Director BUY $11.27 9,000 $101,430 21,914 +69.7%
2013-08-23 01:01 2013-08-20 MANGANO ROSS J Director BUY $7.47 10,000 $74,659 18,550 +117.0%
2005-04-22 23:38 2005-04-21 BELL STEVEN J Officer - VP Research & Pre-Clinical Dev SELL $3.97 1,400 $5,555 875 -61.5%
2005-04-21 23:09 2005-04-12 BELL STEVEN J Officer - VP Research & Pre-Clinical Dev SELL $4.03 2,700 $10,878 2,275 -54.3%
2005-04-20 01:46 2005-04-15 LEHMAN LEAH M Officer - Vice President, Prod. Dev. SELL $3.78 80,377 $304,155 0 -100.0%
2005-04-19 02:23 2005-04-14 LEHMAN LEAH M Officer - Vice President, Prod. Dev. SELL $4.03 29,400 $118,467 80,377 -26.8%
2005-04-13 00:13 2005-04-11 BELL STEVEN J Officer - VP Research & Pre Clinical Dev OPT+S $4.17 8,900 $37,134 4,975 0.0%
2005-01-06 00:15 2005-01-04 MANGANO ROSS J Director, 10% owner BUY $5.02 30,000 $150,588 30,000 +100.0%
2004-12-07 00:28 2004-12-02 EDELMAN JOSEPH 10% owner BUY $3.98 2,000 $7,960 1,877,650 +0.1%
2004-12-07 00:28 2004-12-02 EDELMAN JOSEPH 10% owner SELL $4.66 1,795,000 $8,356,264 209,100 -89.6%
SHOW ENTRIES

How to Interpret $ANIP Trades

Not every insider transaction in Ani Pharmaceuticals Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ANIP shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for ANIP

Insider activity data for Ani Pharmaceuticals Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ANIP, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.